In a report published Wednesday, Stifel analyst Brian Klein downgraded the rating on Synta Pharmaceuticals Corp. SNTA from Hold to Sell.
In the report, Stifel noted, “SNTA reported 4Q13 LPS of $(0.31), in line with our $(0.32) estimate. Due to further delayed data readouts, changes in clinical trial designs, leadership changes, and the further need for capital, we are downgrading Synta (SNTA) to a Sell.”
Synta Pharmaceuticals Corp. closed on Tuesday at $5.28.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in